Author

Timothy Ritter 1

1 GI Alliance,Southlake,United States

ETROLIZUMAB VERSUS PLACEBO IN TUMOR NECROSIS FACTOR ANTAGONIST NAIVE PATIENTS WITH ULCERATIVE COLITIS: RESULTS FROM THE RANDOMIZED PHASE 3 LAUREL TRIAL

Severine Vermeire, Peter L Lakatos, Timothy Ritter, Stephen B Hanauer, Brian Bressler, Reena Khanna, Kim Isaacs, Saumin Shah, Alysha Khavarian Kadva, Helen Tyrrell, Young Oh, Swati Tole, Akiko Chai, Jennifer Pulley, Wenhui Zhang, Brian G. Feagan

RAPIDITY OF SYMPTOM IMPROVEMENTS DURING FILGOTINIB INDUCTION THERAPY IN PATIENTS WITH ULCERATIVE COLITIS: POST HOC ANALYSIS OF THE PHASE 2B/3 SELECTION STUDY

Silvio Danese, Timothy Ritter, Jason Dinoso, Jeremy Hsieh, Chohee Yun, Jie Zhang, Sally Zhao, Edward V Loftus Jr, Toshifumi Hibi, Gerhard Rogler

RATES OF TREATMENT FAILURE AMONG PATIENTS WITH ULCERATIVE COLITIS TREATED WITH FIRST-LINE ADVANCED TREATMENTS

Scott Lee, Kenneth LaPensee, Keith A. Betts, Ella Xiaoyan Du, Xiaoyu Nie, Komal Gupte-Singh, Timothy Ritter

Item 1 - 3 / 3
1